 Now China's Sinovac biotech is in talks about setting up a vaccine production facility in South Africa. It will supply the African continent with shots against a range of diseases. Nomalux Group CEO Hilton Klein made a comment. It was at the launch of the South African leg of a global phase 3 trial of a Sinovac's COVID-19 vaccine in children and adolescents. Sinovac did not immediately respond to a request for comments. Sinovac and Nomalux are rolling 2,000 participants in the South African leg of their study evaluating the efficacy. Also, the immunogenicity and safety of the coronavirus vaccine against COVID-19 on children and adolescents aged 6 months to 17 years. The global trial will enroll 14,000 participants also in Chile, the Philippines, Malaysia and Kenya. So far, more than 10.5 million of the country's 60 million people have received at least one dose of vaccine equivalent to around 17 percent of the population. Take a listen. At the moment, in talks with Sinovac to set up a vaccine manufacturing facility, a phase one where we will do bottling and labelling so that we can get vaccines out to the people of Africa as soon as possible. We say as Nomalux vaccines in Africa for Africa. This clinical trial is a precursor to the establishment of a South African vaccine manufacturing facility partnered by Sinovac and Nomalux Group that will cover the entire spectrum of vaccinations beyond just the COVID-19 response. Hello. Hope you enjoyed the news. Please do subscribe to our YouTube channel and don't forget to hit the notification button so you get notified about fresh news updates.